Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced that its Board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback